Contract Research & Services
Clinical Trials

Win with Networked Drug Development Alliances

Published 07 June 2011 | By INC Research

Large biopharms are caught between two powerful market forces: the pressure to maximize profits and the need for continual investment in their drug pipelines. For drug development executives, choosing which drugs to commercialize is all about trade-offs -- for example, passing over many pre-clinical compounds to aggressively pursue the highest probability clinical trials that maximize the likelihood of near-term revenue and earnings. Executives know that passing over promising compounds could mean missing their next big hit.

Available Downloads

Win with Networked Drug Development Alliances